What Bio Rad Laboratories Doubters Overlooked

Bio-Rad Laboratories spent 2026 talking up digital PCR, from QX700 system launches to new assay partnerships in precision oncology and MRD research. Holding Bio-Rad Laboratories from the start of the year would have returned 21.4%, including dividends. If you had been deciding on 1 January, you would have seen bullish analysts arguing ddPCR could displace older methods and skeptics warning about price controls and obsolescence. Which of those competing stories did buyers need to accept for that outcome to make sense?

Narratives are how investors here put a case on the record, with explicit assumptions about revenue, margins and the multiple. Those assumptions imply an estimated Fair Value.

Bio-Rad Laboratories is not the only name tied to this theme. Zero in on 35 healthcare AI stocks and compare how each one is priced.

The Two Stories Bio-Rad Investors Had To Weigh

Shares in Bio-Rad Laboratories cost US$303 at the start of the period, and investors had to decide which story about digital PCR and diagnostics felt more credible.

The bullish narrative put Fair Value at US$437, or 44% above the start price, assuming revenue growth of 3.7% a year and profit margins easing to 7.7%. That view leaned on ddPCR displacing legacy methods and a future P/E of 59.2x.

The bearish case pointed to price pressure and funding cuts, with Fair Value at US$265, or 13% below the start price. It assumed slower revenue growth of 1.9%, profit margins of 8.2%, and a future P/E of 35.8x as reimbursement and regulation squeezed diagnostics.

What The Results Changed For The Bio-Rad Laboratories Story

Bio-Rad Laboratories delivered a sharp swing in profitability, with net income moving from a loss of US$341.9 million in Q3 2025 to a profit of US$458.6 million in Q3 2026. Revenue shifted from US$653 million to US$656.4 million and net margin rose from -52.4% to 69.9%, which leaned toward the optimistic digital PCR case, although the short window kept the story partly open.

The hinge assumption here was that ddPCR and diagnostics strength would eventually show up in earnings quality, not just sales. When you look at another diagnostics stock, test whether margin direction and absolute profit line up with whatever growth story you are being asked to believe.

What Bio-Rad’s Price Now Asks You To Believe

Bio-Rad Laboratories now trades at US$370 from the start of the year, so the stock is up 21.4%. The bearish analyst Narrative on Simply Wall St places its Fair Value below that level, arguing the current tag already bakes in a smoother clean-up story.

That Narrative focuses on flat revenue guidance, margin strain and exposure to funding swings in places like China. A buyer today is effectively assuming ddPCR focus, productivity tools and portfolio reshaping offset those pressures. How does that assumption square with the concrete guidance cuts and cost issues highlighted?

"The current valuation implies that Bio-Rad Laboratories is priced for a smoother recovery in growth and margins than its recent guidance for flat to slightly declining 2026 revenue and 10% to 12% non-GAAP operating margin suggests."

One Narrative has put a figure on that disagreement. → See the Narrative with its lower Fair Value, assumptions and all

Bio-Rad And A Parallel Bet

Bio-Rad shows how a focused technology story can reshape expectations for a business.

You could also look sideways, at another healthcare giant solving a different problem.

Where Bio-Rad leans on diagnostics and ddPCR, this other business leans on new medicines.

It works on treatments for wide ranging conditions, from infections to cancer, with a pitch built on fresh products, a deep pipeline and cost cuts.

If that shift holds, investors are weighing whether a broad medicine portfolio can keep renewing itself over time.

It is written up in full, assumptions and all. → Explore the Narrative that puts this company 28% above its price

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com